218. Alport syndrome Clinical trials / Disease details
Clinical trials : 26 / Drugs : 33 - (DrugBank : 13) / Drug target genes : 6 - Drug target pathways : 29
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04937907 (ClinicalTrials.gov) | September 8, 2021 | 17/6/2021 | Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS) | Efficacy and Safety of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS) | Alport Syndrome, X-Linked | Drug: Hydroxychloroquine Sulfate 100 milligram (mg) Tab;Drug: Benazepril hydrochloride 10 milligram (mg) Tab | Shanghai Children's Hospital | NULL | Recruiting | 3 Years | 18 Years | All | 50 | Phase 2 | China |